Search

Your search keyword '"Adams, Kirkwood"' showing total 910 results

Search Constraints

Start Over You searched for: Author "Adams, Kirkwood" Remove constraint Author: "Adams, Kirkwood"
910 results on '"Adams, Kirkwood"'

Search Results

1. Abstract 4140480: The Relationship Between Obesity Status and Change in NT-proBNP with Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Recent Worsening Heart Failure Event: Results from the PARAGLIDE-HF Trial

2. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF

4. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

6. Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies)

7. Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study

8. Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction

9. Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial

10. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure

12. Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF)

14. Charting a Roadmap for Heart Failure Biomarker Studies

15. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

16. Effective medications can work only in patients who take them: implications for post acute heart failure care

19. Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF

23. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

26. Effective medications can work only in patients who take them: Implications for post‐acute heart failure care.

27. Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators

29. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial

30. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial

37. Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial.

39. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

42. Abstract 15360: Biomarker-Guided Heart Failure Therapy Results in Significant Reverse Left Ventricular Remodeling Among Patients Achieving NT-proBNP Goal: Insights From the GUIDE-IT Trial

47. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

50. The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial

Catalog

Books, media, physical & digital resources